'Friend-Raising' For Biomedical Research: What Are You Waiting For?

What Are You Waiting For? (The Scientist, Vol:10, #6, p. 10, March 18, 1996) It is my experience that clinicians and scientists explain their reluctance to become personally involved in advocacy for medical research on the basis of one or more of the following rationalizations: "My efforts won't make any difference." "I don't know how." "I don't have time, and besides, it's not seemly to do so." Rarely do I hear that advocacy isn't necessary, least of all in these times of unprecedented threat

Written byMary Woolley
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

What Are You Waiting For? (The Scientist, Vol:10, #6, p. 10, March 18, 1996)

It is my experience that clinicians and scientists explain their reluctance to become personally involved in advocacy for medical research on the basis of one or more of the following rationalizations: "My efforts won't make any difference." "I don't know how." "I don't have time, and besides, it's not seemly to do so."

Rarely do I hear that advocacy isn't necessary, least of all in these times of unprecedented threats to funding of the National Institutes of Health, but advocacy is usually regarded as somebody s job. If indeed it were ever true that advocacy is the exclusive purview of only a few (deans, presidents, society leaders, voluntary health organizations), that system is not working any more!

If we don't all become comfortable with the fact that advocacy is part of our jobs now, funding will ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies